Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader...
20 insider purchases on record · latest filing 2025-05-22.
Insiders have also filed 4 sale transactions at ATOS.